Nivolumab, the second PD-1-targeting checkpoint inhibitor approved for melanoma, was compared to investigator choice chemotherapy (ICC) as second- or later-line treatment in patients who were refractory to ipilimumab or BRAF agents. The gene discussed is BRAF; the disease is melanoma.